Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Fujian Medical University Union Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website: http://www.fjxiehe.com/

Clinical Trials

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Insomnia with Subjective Cognitive Decline

Not Applicable

Not yet recruiting

Conditions: Insomnia Chronic
Subjective Cognitive Decline (SCD)

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 66

Registration Number: NCT06710652

Efficacy, Safety of Astragalus Membranaceus in Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Astragalus Membranaceus Root

First Posted Date: 2024-11-19

Last Posted Date: 2024-11-19

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 76

Registration Number: NCT06694597

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma

Not Applicable

Recruiting

Conditions: Melasma

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 60

Registration Number: NCT06677931

Locations: 🇨🇳
Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
Chenxiaosong, Fujian, fuzhou, China

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Phase 2

Not yet recruiting

Conditions: NMIBC

Interventions: Drug: Distitamab Vedotin in combination with Tislelizumab

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-10

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 40

Registration Number: NCT06630871

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Serplulimab
Drug: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
Drug: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
Radiation: Radiotherapy

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 90

Registration Number: NCT06601309

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities

Phase 2

Recruiting

Conditions: Soft Tissue Sarcomas

Interventions: Radiation: Hypofractionated Radiotherapy
Drug: 3 cycles of AI

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 51

Registration Number: NCT06593899

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

Phase 3

Recruiting

Conditions: Breast Cancer

First Posted Date: 2024-08-19

Last Posted Date: 2024-08-19

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 722

Registration Number: NCT06559696

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Phase 2

Recruiting

Conditions: Biomarkers
Esophageal Squamous Cell Carcinoma
Immunotherapy

Interventions: Drug: adebrelimab

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 48

Registration Number: NCT06510660

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia

Phase 4

Recruiting

Conditions: Cardiac Function
Breast Cancer
Neoadjuvant Chemotherapy
Perioperative Period
Anaesthesia

Interventions: Drug: Deoxyadrenaline
Drug: normal saline

First Posted Date: 2024-07-12

Last Posted Date: 2025-03-04

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 496

Registration Number: NCT06497660

Locations: 🇨🇳
Fujian Medical University Affiliated Union Hospital, Fuzhou, Fujian, China

Study of Health Behavior in Patients After Heart Valve Replacement： Longitudinal Studies

Recruiting

Conditions: Health Behavior
Postoperative Period
Heart Valve Diseases

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 219

Registration Number: NCT06490952

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy